Pcas: NET SALES AS OF MARCH 31, 2023
24 April 2023 - 6:00PM
Pcas: NET SALES AS OF MARCH 31, 2023
Ecully, April 24, 2023
NET SALES AS OF MARCH 31,
2023
PCAS (Euronext Paris: PCA), a
specialist in developing and producing complex molecules for life
sciences and innovative technologies, has announced the publication
of its consolidated net sales as of March 31, 2023.
The PCAS Group has generated consolidated net
sales of €66.2 million as of March 31, 2023, a 29.4% increase
compared to the same period during the previous financial year
(+28.3% at a constant exchange rate).
|
In millions of euros |
|
2023 |
|
2022 |
|
% change |
|
2023 At a constant exchange rate |
|
% change |
|
|
|
|
|
|
|
|
|
|
|
|
| Sales
as of 31 March |
|
66.2 |
|
51.2 |
|
29.4% |
|
65.7 |
|
28.3% |
| Pharmaceutical
Synthesis |
|
43.5 |
|
31.3 |
|
39.0% |
|
43.4 |
|
38.5% |
|
Fine Specialty Chemicals |
|
22.7 |
|
19.9 |
|
14.2% |
|
22.3 |
|
12.1% |
|
in millions of euros |
France |
Other areas |
Total |
|
|
|
|
|
| Net Sales
by origin |
|
|
|
| March 31,
2023 |
49.8 |
16.4 |
66.2 |
| March 31,
2022 |
39.0 |
12.2 |
51.2 |
|
|
|
|
|
Pharmaceutical Synthesis
The Pharmaceutical Synthesis business generated
sales of €43.5 million, a 39.0% increase compared to 2022 (a 38.5%
increase at a constant exchange rate). Rising net sales can be
attributed primarily to a higher demand in R&D and in most
production sites as well as the price increase policy initiated in
2022 to cope with the rising costs of raw materials, energy and
supplies.
Fine Specialty Chemicals
Net sales of Fine Specialty Chemicals totaled
€22.7 million, a 14.2% increase compared to 2022 (a 12.1%
increase at a constant exchange rate). Business levels are still
high in the first months of the year, with a very strong demand for
Electronics and Fine Chemicals. A slight slowdown can be observed
in the Lubricants business. The industrialization of new products
is still at a good level across all sites.
Outlook
In the context of the ongoing dispute with
Mithra, PCAS continues to study a temporary reduction in activity
in 2023 on the production site where certain workshops are
dedicated to the production of Estetrol. At this stage, it is still
not possible to precisely assess the consequences of this dispute
on future business and results.
As stated in the press release of March 30,
2023, as a consequence, the return to positive results announced
for 2023 is delayed.
PCAS Group will continue to benefit from the
support of its majority shareholder Seqens (owning 76.66%) for the
financing of its activities and its development.
NEXT FINANCIAL DISCLOSURE:
Net Sales as of June 30,2023 - July 27, 2023
ABOUT PCAS
PCAS specializes in the development and
production of complex molecules for life sciences and innovative
technologies. With about 11% of its net sales earmarked for R&D
and a large international footprint, PCAS is the preferred
industrial partner for market-leading major global groups. Boasting
especially high standards, the company offers a growing range of
proprietary products and solutions in leading-edge segments. PCAS
generated net sales of €226.4 million in 2022 and employs nearly
1200 people in six countries.
To find out more about PCAS: www.pcas.com
|
PCAS |
NewCap |
|
Jean-Louis Martin / Eric Moissenot |
Emmanuel Huynh / Louis-Victor Delouvrier
NewCapFinancial communication and investor
relation |
|
|
|
|
Tel.: +33 1 69 79 60 00www.pcas.com |
Tel.: +33 1 44 71 98 53pcas@newcap.eu |
| |
|
- PCAS - Communiqué de presse - Chiffre d'affaires au 31 mars
2023_US - DEF
PCAS (EU:PCA)
Historical Stock Chart
Von Apr 2024 bis Mai 2024
PCAS (EU:PCA)
Historical Stock Chart
Von Mai 2023 bis Mai 2024
